China Resources Pharmaceutical Group Ltd. (640) Price & Analysis

0 Followers

640 Stock Chart & Stats

€0.49

€0.00(0.00%)

At close: Jan 08 4:00 PM EST

€0.49

€0.00(0.00%)

Day’s Range― - ―

52-Week Range€0.45 - €0.71

Previous CloseN/A

Volume0.00

Average Volume (3M)31.00

Market Cap

€2.95B

Enterprise Value€173.67K

Total Cash (Recent Filing)€44.03B

Total Debt (Recent Filing)€114.17B

Price to Earnings (P/E)5.7

Beta0.25

Next EarningsN/A

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)N/A

Shares Outstanding6,282,510,300

10 Day Avg. Volume35

30 Day Avg. Volume31

Financial Highlights & Ratios

PEG Ratio0.22

Price to Book (P/B)0.49

Price to Sales (P/S)0.09

P/FCF Ratio1.48

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€0.72

Price Target Upside46.86% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Integrated Business ModelVertical integration across distribution, retail and manufacturing creates durable revenue diversification and supply‑chain control. This reduces dependence on a single channel, enables cross‑selling and inventory efficiency, supporting stable cash flow and resilience over months.

Strong Cash GenerationConsistently strong operating and free cash flow relative to earnings improves financial flexibility for capex, dividends and debt servicing. Reliable cash conversion supports strategic investments and cushions the business against cyclical pressures over the medium term.

Steady Revenue And Operating ProfitabilityReturn to mid‑single‑digit revenue growth and stable operating margins indicate underlying demand and operational stability. Consistent top‑line expansion plus modest operating margin improvement supports sustainable earnings power and reinvestment capacity over 2–6 months.

Bears Say

Very Thin Net MarginsNet margins near 1–1.5% leave little room for error: small cost increases or pricing pressure materially reduce profits. Limited bottom‑line leverage constrains retained earnings, weakens return sensitivity, and hampers long‑term capacity to build equity organically.

Rising LeverageMaterial rise in leverage increases interest burden and financial risk, reducing flexibility for M&A or capital spending. Elevated debt levels amplify downside in an adverse environment and make the company more sensitive to credit conditions over the medium term.

Low Debt Coverage By Cash FlowOperating cash flow covers a tiny fraction of total debt, limiting the company’s ability to deleverage quickly. This structural cash‑coverage gap constrains capital allocation choices and raises refinancing or liquidity risk if market conditions tighten.

China Resources Pharmaceutical Group Ltd. News

China Resources Pharma Subsidiary KPC Wins Approval for RMB1 Billion Medium-Term Note Program

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ). China Resources Pharmaceutical Group...

14d ago

China Resources Pharma unit posts H1 2026 unaudited results tied to onshore bond issues

The latest announcement is out from China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ). China Resources Pharmaceutical Group...

15d ago

CR Pharmaceutical subsidiary posts unaudited interim results tied to PRC bond issuance

China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has shared an announcement. China Resources Pharmaceutical Group Ltd. has...

15d ago

China Resources Pharmaceutical Posts Stable Interim Profit and Higher Revenue

An update from China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) is now available. China Resources Pharmaceutical Group...

22d ago

China Resources Pharmaceutical Declares Interim Dividend with Currency Option

China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has provided an announcement. China Resources Pharmaceutical Group Limited has...

22d ago

China Resources Pharma Flags Sharp Interim Loss at KPC Subsidiary

The latest update is out from China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ). China Resources Pharmaceutical Group...

25d ago

CR Sanjiu H1 2026 Profit Declines Amid Modest Revenue Growth, Dividend Proposed

China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has issued an update. China Resources Sanjiu Medical & Pharmaceutical...

25d ago

Tasly Pharmaceutical Posts Strong Profit and Cash Flow Despite Flat Revenue

An announcement from China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) is now available. Tasly Pharmaceutical reported unaudited...

25d ago

CR Jiangzhong Posts Lower Interim Earnings but Boosts Operating Cash Flow and Keeps Dividend

China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has issued an announcement. CR Jiangzhong reported unaudited interim results...

25d ago

CR Double-Crane Posts Softer Interim Earnings but Maintains Dividend Payout

China Resources Pharmaceutical Group Ltd. ( ($HK:3320) ) has provided an update. China Resources Double-Crane Pharmaceutical Co., Ltd.,...

25d ago

640 FAQ

What was China Resources Pharmaceutical Group Ltd.’s price range in the past 12 months?

China Resources Pharmaceutical Group Ltd. lowest stock price was €0.45 and its highest was €0.71 in the past 12 months.

What is China Resources Pharmaceutical Group Ltd.’s market cap?

China Resources Pharmaceutical Group Ltd.’s market cap is €2.95B.

When is China Resources Pharmaceutical Group Ltd.’s upcoming earnings report date?

The company’s upcoming earnings report date is not yet available.

How were China Resources Pharmaceutical Group Ltd.’s earnings last quarter?

Currently, no data Available

Is China Resources Pharmaceutical Group Ltd. overvalued?

According to Wall Street analysts China Resources Pharmaceutical Group Ltd.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does China Resources Pharmaceutical Group Ltd. pay dividends?

China Resources Pharmaceutical Group Ltd. does not currently pay dividends.

What is China Resources Pharmaceutical Group Ltd.’s EPS estimate?

China Resources Pharmaceutical Group Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does China Resources Pharmaceutical Group Ltd. have?

China Resources Pharmaceutical Group Ltd. has 6,282,510,300 shares outstanding.

What happened to China Resources Pharmaceutical Group Ltd.’s price movement after its last earnings report?

Currently, no data Available

Which hedge fund is a major shareholder of China Resources Pharmaceutical Group Ltd.?

Currently, no hedge funds are holding shares in DE:640

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

China Resources Pharmaceutical Group Ltd. Stock Smart Score

Neutral

Analyst Consensus

Strong Buy

Average Price Target:
€0.72 (46.86% Upside)

Technicals

Fundamentals

Return on Equity

5.52%

Trailing 12-Months

Asset Growth

11.25%

Trailing 12-Months

Learn more about TipRanks Smart Score

Top Smart Score Stocks >

Company Description

China Resources Pharmaceutical Group Ltd.

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular and cerebrovascular diseases, alimentary tract, endocrine diseases, respiratory diseases, orthopedics, nephrology, rheumatology and immunology, medical nutrition, pediatrics, genitourinary system, dermatological diseases, blood products, therapeutic infusions, antitumor drugs, medicine for cough and cold, anti-infection drugs, and psychoneurosis. It also provides warehousing, logistics, and other value-added pharmaceutical supply chain solutions and related services to pharmaceutical/medical device manufacturers and dispensers, such as hospitals, distributors, and retail pharmacies. In addition, the company is involved in property holding activities, as well as operates retail pharmacies under the Teck Soon Hong brands. It distributes its products under the 999, Dong-E-E-Jiao, Double Crane, Zizhu, Jiangzhong, Boya, and Kun Zhong Yao to hospitals and other medical institutions. The company was formerly known as China Resources Medications Group Limited and changed its name to China Resources Pharmaceutical Group Limited in December 2011. The company was incorporated in 2007 and is based in Wan Chai, Hong Kong. China Resources Pharmaceutical Group Limited is a subsidiary of CRH (Pharmaceutical) Limited.

China Resources Pharmaceutical Group Ltd. (640) Earnings & Revenues

Historic Earnings Reports

640 Stock 12 Month Forecast

Average Price Target

€0.72

▲(46.86% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"€0","1":"€1","-1":"-€1","-0.5":"-€0.5","0.5":"€0.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":0.7922232,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€0.79</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.71960274,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€0.72</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.6271767,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.63</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.5,0,0.5,1],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.463,0.48832486153846155,0.5136497230769231,0.5389745846153846,0.5642994461538462,0.5896243076923077,0.6149491692307693,0.6402740307692307,0.6655988923076923,0.6909237538461539,0.7162486153846154,0.7415734769230768,0.7668983384615384,{"y":0.7922232,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.463,0.48273867230769235,0.5024773446153846,0.522216016923077,0.5419546892307693,0.5616933615384616,0.5814320338461538,0.6011707061538462,0.6209093784615385,0.6406480507692308,0.6603867230769231,0.6801253953846154,0.6998640676923077,{"y":0.71960274,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.463,0.47562897692307693,0.4882579538461539,0.5008869307692307,0.5135159076923077,0.5261448846153847,0.5387738615384616,0.5514028384615385,0.5640318153846154,0.5766607923076923,0.5892897692307693,0.6019187461538462,0.6145477230769232,{"y":0.6271767,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":0.489,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.492,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.516,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.492,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.45,"date":1767225600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.443,"date":1769904000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.454,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.62,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.52,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.483,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.455,"date":1782864000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":0.512,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.463,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >